鼻咽癌免疫检查点抑制剂治疗及相关不良反应研究进展
Research Advances in Immune Checkpoint Inhibitor Therapy and Associated Adverse Effects for Nasopharyngeal Carcinoma
DOI: 10.12677/acrem.2025.133037, PDF,   
作者: 李镜光：右江民族医学院研究生学院，广西 百色；瞿申红：广西壮族自治区人民医院耳鼻咽喉头颈外科，广西 南宁
关键词: 鼻咽癌；免疫检查点抑制剂；PD-1/PD-L1；CTLA-4；免疫治疗相关不良反应；Nasopharyngeal Carcinoma； Immune Checkpoint Inhibitors； PD-1/PD-L1； CTLA-4； Immune-Related Adverse Events
摘要: 鼻咽癌是一种与EB病毒感染密切相关的上皮恶性肿瘤，在中国南方地区高发。尽管现代精准放疗技术显著改善了局部晚期患者的预后，但局部复发和远处转移仍是影响患者长期生存的主要因素。近年来，以PD-1/PD-L1抑制剂为代表的免疫检查点抑制剂在鼻咽癌治疗中展现出显著疗效，为鼻咽癌患者提供了新的治疗选择。然而，这类治疗引发的免疫治疗相关不良反应涉及多器官系统损害，从常见的皮肤、内分泌及消化系统反应，到罕见但可能致命的心肌炎、肺炎等，均需引起临床关注。本文综述了鼻咽癌免疫检查点抑制剂治疗的研究进展及相关不良反应管理策略，以期为鼻咽癌免疫治疗实践提供参考。
Abstract: Nasopharyngeal carcinoma (NPC), an epithelial malignancy strongly associated with Epstein-Barr virus (EBV) infection, is highly prevalent in southern China. Although modern precision radiotherapy has significantly improved outcomes for locally advanced patients, local recurrence and distant metastasis remain major challenges to long-term survival. In recent years, immune checkpoint inhibitors (ICIs), particularly PD-1/PD-L1 inhibitors, have demonstrated remarkable efficacy in NPC treatment, offering new therapeutic options. However, these therapies also trigger a spectrum of immune-related adverse events (irAEs), ranging from common cutaneous, endocrine, and gastrointestinal reactions to rare yet potentially fatal conditions such as myocarditis and pneumonitis, which require careful clinical attention. This review summarizes the latest advances in ICI therapy for NPC and discusses evidence-based strategies for managing irAEs, aiming to offer guidance for optimizing clinical practice.
文章引用：李镜光, 瞿申红. 鼻咽癌免疫检查点抑制剂治疗及相关不良反应研究进展 [J]. 亚洲急诊医学病例研究, 2025, 13(3): 259-264. https://doi.org/10.12677/acrem.2025.133037

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Lee, A.W.M., Ng, W.T., Chan, J.Y.W., Corry, J., Mäkitie, A., Mendenhall, W.M., et al. (2019) Management of Locally Recurrent Nasopharyngeal Carcinoma. Cancer Treatment Reviews, 79, Article ID: 101890. [Google Scholar] [CrossRef] [PubMed]
[3] Xu, T., Tang, J., Gu, M., Liu, L., Wei, W. and Yang, H. (2013) Recurrent Nasopharyngeal Carcinoma: A Clinical Dilemma and Challenge. Current Oncology, 20, 406-419. [Google Scholar] [CrossRef] [PubMed]
[4] Lee, A.W.M., Ma, B.B.Y., Ng, W.T. and Chan, A.T.C. (2015) Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. Journal of Clinical Oncology, 33, 3356-3364. [Google Scholar] [CrossRef] [PubMed]
[5] Wong, K.C.W., Hui, E.P., Lo, K., Lam, W.K.J., Johnson, D., Li, L., et al. (2021) Nasopharyngeal Carcinoma: An Evolving Paradigm. Nature Reviews Clinical Oncology, 18, 679-695. [Google Scholar] [CrossRef] [PubMed]
[6] Chen, Y., Chan, A.T.C., Le, Q., Blanchard, P., Sun, Y. and Ma, J. (2019) Nasopharyngeal Carcinoma. The Lancet, 394, 64-80. [Google Scholar] [CrossRef] [PubMed]
[7] Tsao, S.W., Tsang, C.M. and Lo, K.W. (2017) Epstein-Barr Virus Infection and Nasopharyngeal Carcinoma. Philosophical Transactions of the Royal Society B: Biological Sciences, 372, Article ID: 20160270. [Google Scholar] [CrossRef] [PubMed]
[8] Jin, S., Li, R., Chen, M., Yu, C., Tang, L., Liu, Y., et al. (2020) Single-Cell Transcriptomic Analysis Defines the Interplay between Tumor Cells, Viral Infection, and the Microenvironment in Nasopharyngeal Carcinoma. Cell Research, 30, 950-965. [Google Scholar] [CrossRef] [PubMed]
[9] Liu, Y., He, S., Wang, X., Peng, W., Chen, Q., Chi, D., et al. (2021) Tumour Heterogeneity and Intercellular Networks of Nasopharyngeal Carcinoma at Single Cell Resolution. Nature Communications, 12, Article No. 741. [Google Scholar] [CrossRef] [PubMed]
[10] Wang, J., Luo, Y., Bi, P., Lu, J., Wang, F., Liu, X., et al. (2020) Mechanisms of Epstein‐Barr Virus Nuclear Antigen 1 Favor Tregs Accumulation in Nasopharyngeal Carcinoma. Cancer Medicine, 9, 5598-5608. [Google Scholar] [CrossRef] [PubMed]
[11] Kaidar-Person, O., Gil, Z. and Billan, S. (2018) Precision Medicine in Head and Neck Cancer. Drug Resistance Updates, 40, 13-16. [Google Scholar] [CrossRef] [PubMed]
[12] Xiao, Y., Qing, J., Li, B., Chen, L., Nong, S., Yang, W., et al. (2020) Tim-3 Participates in the Invasion and Metastasis of Nasopharyngeal Carcinoma via SMAD7/SMAD2/SNAIL1 Axis-Mediated Epithelial-Mesenchymal Transition. OncoTargets and Therapy, 13, 1993-2006. [Google Scholar] [CrossRef] [PubMed]
[13] Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., et al. (2022) The Role of PD-1/PD-L1 and Application of Immune-Checkpoint Inhibitors in Human Cancers. Frontiers in Immunology, 13, Article ID: 964442. [Google Scholar] [CrossRef] [PubMed]
[14] Johnson, D. and Ma, B.B.Y. (2021) Targeting the PD-1/PD-L1 Interaction in Nasopharyngeal Carcinoma. Oral Oncology, 113, Article ID: 105127. [Google Scholar] [CrossRef] [PubMed]
[15] Hsu, C., Lee, S., Ejadi, S., Even, C., Cohen, R.B., Le Tourneau, C., et al. (2017) Safety and Antitumor Activity of Pembrolizumab in Patients with Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. Journal of Clinical Oncology, 35, 4050-4056. [Google Scholar] [CrossRef] [PubMed]
[16] Chan, A.T.C., Lee, V.H.F., Hong, R., Ahn, M., Chong, W.Q., Kim, S., et al. (2023) Pembrolizumab Monotherapy versus Chemotherapy in Platinum-Pretreated, Recurrent or Metastatic Nasopharyngeal Cancer (KEYNOTE-122): An Open-Label, Randomized, Phase III Trial. Annals of Oncology, 34, 251-261. [Google Scholar] [CrossRef] [PubMed]
[17] Mai, H., Chen, Q., Chen, D., Hu, C., Yang, K., Wen, J., et al. (2023) Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. JAMA, 330, 1961-1970. [Google Scholar] [CrossRef] [PubMed]
[18] Yang, Y., Qu, S., Li, J., Hu, C., Xu, M., Li, W., et al. (2021) Camrelizumab versus Placebo in Combination with Gemcitabine and Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN-1st): A Multicentre, Randomised, Double-Blind, Phase 3 Trial. The Lancet Oncology, 22, 1162-1174. [Google Scholar] [CrossRef] [PubMed]
[19] Yang, Y., Pan, J., Wang, H., Zhao, Y., Qu, S., Chen, N., et al. (2023) Tislelizumab Plus Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer: A Multicenter Phase 3 Trial (RATIONALE-309). Cancer Cell, 41, 1061-1072.e4. [Google Scholar] [CrossRef] [PubMed]
[20] Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z. and Baradaran, B. (2020) CTLA-4: From Mechanism to Autoimmune Therapy. International Immunopharmacology, 80, Article ID: 106221. [Google Scholar] [CrossRef] [PubMed]
[21] Keam, S.J. (2022) Cadonilimab: First Approval. Drugs, 82, 1333-1339. [Google Scholar] [CrossRef] [PubMed]
[22] Chen, Q., Guo, S., Luo, Y., Qu, S., Wu, D., Chen, X., et al. (2024) Efficacy and Safety of Cadonilimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (COMPASSION-06): A Phase II Multicenter Study. Oral Oncology, 151, Article ID: 106723. [Google Scholar] [CrossRef] [PubMed]
[23] Blum, S.M., Rouhani, S.J. and Sullivan, R.J. (2023) Effects of Immune‐Related Adverse Events (IRAES) and Their Treatment on Antitumor Immune Responses. Immunological Reviews, 318, 167-178. [Google Scholar] [CrossRef] [PubMed]
[24] Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L.L. and Hansen, A.R. (2017) Tumour-and Class-Specific Patterns of Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Annals of Oncology, 28, 2377-2385. [Google Scholar] [CrossRef] [PubMed]
[25] Mahmood, S.S., Fradley, M.G., Cohen, J.V., Nohria, A., Reynolds, K.L., Heinzerling, L.M., et al. (2018) Myocarditis in Patients Treated with Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 71, 1755-1764. [Google Scholar] [CrossRef] [PubMed]
[26] Wang, D.Y., Salem, J., Cohen, J.V., Chandra, S., Menzer, C., Ye, F., et al. (2018) Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors. JAMA Oncology, 4, 1721-1728. [Google Scholar] [CrossRef] [PubMed]
[27] Naidoo, J., Wang, X., Woo, K.M., Iyriboz, T., Halpenny, D., Cunningham, J., et al. (2017) Pneumonitis in Patients Treated with Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of Clinical Oncology, 35, 709-717. [Google Scholar] [CrossRef] [PubMed]
[28] Stamatouli, A.M., Quandt, Z., Perdigoto, A.L., Clark, P.L., Kluger, H., Weiss, S.A., et al. (2018) Collateral Damage: Insulin-Dependent Diabetes Induced with Checkpoint Inhibitors. Diabetes, 67, 1471-1480. [Google Scholar] [CrossRef] [PubMed]
[29] Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F.L., Carbonnel, F., et al. (2016) Safety Profiles of Anti-CTLA-4 and Anti-PD-1 Antibodies Alone and in Combination. Nature Reviews Clinical Oncology, 13, 473-486. [Google Scholar] [CrossRef] [PubMed]
[30] Tang, L., Chen, Y., Chen, C., Chen, M., Chen, N., Chen, X., et al. (2021) The Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for the Diagnosis and Treatment of Nasopharyngeal Carcinoma. Cancer Communications, 41, 1195-1227. [Google Scholar] [CrossRef] [PubMed]

为你推荐